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e-Evaluating Therapeutic
arget Goals for Statin-Treated
atients
ime for Revolutionary Changes?*
aakov Henkin, MD
eer Sheva, Israel
“God, give us grace to accept with serenity the things that cannot be
changed, courage to change the things which should be changed, and
the wisdom to distinguish the one from the other.”
—Reinhold Niebuhr (1892–1971) (1)
ver since Anitschkow’s pioneering experiments on the role
f cholesterol in the causation of atherosclerotic plaques in
abbits (2), this intriguing molecule has been at the heart of
ebate and controversy (3). Initially, the total cholesterol
evel was used as a measure of risk, then a distinction
etween - and -lipoproteins emerged. As the role of
pecific lipoproteins became clear, attention focused on the
holesterol content of low-density lipoprotein (LDL),
hich constitutes the major cholesterol-carrying lipoprotein
n serum. The National Cholesterol Education Program’s
dult Treatment Program (ATP), first published in 1988,
See page 626
ecommended using the LDL cholesterol level as the
arker for initiating treatment as well as for gauging
herapeutic target goals (4). The well orchestrated campaign
hat followed these guidelines familiarized the medical
ommunity with LDL cholesterol. Since then numerous
linical studies have confirmed the value of nutritional and
harmacologic treatment of hypercholesterolemia, and the
evelopment of newer and more potent drugs resulted in a
rogressive lowering of the recommended LDL cholesterol
arget levels for patients at high risk of coronary heart
isease (CHD) (5–8).
However, despite the abundant data relating LDL to
therosclerosis, it became clear that focusing solely on the
ipoprotein cholesterol content may have its flaws. The
redictive power of the LDL cholesterol level for CHD has
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or theg
merican College of Cardiology.
From the Soroka University Medical Center, Beer Sheva, Israel.een challenged, and it has been advocated that the number
f atherogenic lipoprotein particles is more predictive of
HD than their cholesterol content (9–11). This distinc-
ion is relevant, because the 2 parameters are not always in
ccord. Because direct measurement of LDL cholesterol
evels is cumbersome and expensive, most clinical laborato-
ies report the calculated LDL cholesterol values using the
riedwald formula (12). Although this approach appears to
e reasonable in normotriglyceridemic patients, the struc-
ural composition of the LDL molecule becomes distorted
n hypertriglyceridemia and certain related conditions (13–
5). As a result, the relationship between the calculated
DL cholesterol level and the number of LDL particles is
odified. In addition, several triglyceride-rich lipoprotein
articles, including very-low-density lipoprotein (VLDL)
emnants and intermediate-density lipoprotein (IDL), ap-
ear to be atherogenic (16,17). Whereas IDL is included
ithin the calculated LDL cholesterol, VLDL is excluded.
Many (11,18–23), but not all (24–26), studies indicate
hat the apolipoprotein (apo) B level, which represents the
otal number of atherogenic lipoprotein particles (each
article contains a single apoB molecule), better correlates
ith CHD than the LDL cholesterol level in untreated as
ell as statin-treated individuals. Similarly, a growing num-
er of studies suggest that the non–high-density lipoprotein
holesterol (HDL-C) level, which represents the cholesterol
arried in all atherogenic apoB-containing lipoproteins, is
lso superior to LDL cholesterol level in predicting CHD
11,20,27–31). This is especially true in diabetic and/or
ypertriglyceridemic individuals. Finally, the whole concept
f monitoring treatment success by laboratory parameters
as recently been challenged, claiming that the statin dose is
ore relevant than the LDL cholesterol level achieved (32).
espite these claims, LDL cholesterol has retained its role
s the primary indicator for initiating treatment and target-
ng therapeutic goals in both the ATP III as well as the joint
uropean guidelines (6). The major reason for this ap-
roach was the feeling that LDL is deeply rooted in the
inds of most physicians as the primary therapeutic target,
nd replacing it with apoB in the absence of stronger
vidence might generate considerable confusion (8,33). The
TP III guidelines did adopt non–HDL-C as a secondary
nd point, but only in patients with triglyceride levels in the
ange of 200 to 499 mg/dl and after achieving target LDL
holesterol goals. Although formal data on the acceptability
f this 2-step approach by the medical community are
acking, it has been shown that achievement of the recom-
ended non–HDL-C goals is less than optimal (34),
uggesting that the adoption of non–HDL-C as a target
oal by physicians, patients, and laboratories is still faltering.
recent consensus statement from the American Diabetes
ssociation and the American College of Cardiology
oundation to guide the therapy of patients with cardio-
etabolic risk suggested using apoB as a therapeuticuide in addition to LDL and non–HDL-C (8).
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Editorial Comment August 19, 2008:633–5In the current issue of the Journal, Ballantyne et al. (35)
rovide additional fuel for the debate by examining the
elationship between apoB, LDL cholesterol, and non–
DL-C levels before and after 16 weeks of statin therapy in
,993 high-risk dyslipidemic individuals enrolled in the MER-
URY II (Measuring Effective Reductions in Cholesterol
sing Rosuvastatin Therapy II) trial. More specifically, they
valuated the levels of LDL cholesterol and non–HDL-C
hat corresponded to an apoB level of 90 mg/dl, which had
een proposed as the target apoB level in high-risk individ-
als (8,33). They found that in untreated patients, this apoB
evel roughly corresponds to an LDL cholesterol level of
100 mg/dl and a non–HDL-C level of 130 mg/dl,
hich is in agreement with current ATP III–recommended
arget values in high-risk individuals. However, statin ther-
py altered this relationship so that it was necessary to
educe non–HDL-C to 100 mg/dl and LDL-C to 70
g/dl (in high-triglyceride patients) or 80 mg/dl (in
ow-triglyceride patients) to achieve the apoB target of 90
g/dl. This results from the fact that statin therapy reduces
he cholesterol content in LDL to a greater extent than the
eduction in apoB (36) and implies that relying on LDL
holesterol as the therapeutic target might overestimate
reatment effect. The authors interpret these results as
vidence that in statin-treated patients the optimal target
oals should be 70 to 80 mg/dl for LDL cholesterol and
100 mg/dl for non–HDL-C. Current ATP III guidelines
ecommend these levels as “optional” target goals only for
ndividuals with cardiovascular disease who continue to
arbor risk factors (such as diabetes, cigarette smoking, or
ultiple risk factors for metabolic syndrome) that render
hem at very high risk for recurrent events or after an acute
oronary syndrome, but they maintain less ambitious goals
or “standard” high-risk individuals. Therefore, if the gold
tandard target goal is truly an apoB level of 90 mg/dl, the
very-high-risk target goals” should be adopted for all CHD
nd CHD-equivalent patients. However, the choice of 90
g/dl as the apoB target goal does not seem to be based on
obust clinical evidence but rather on limited epidemiologic,
ost hoc analyses, and “expert opinion” (33,37,38). Achiev-
ng these goals is feasible in less than one-half of high-risk
atients, even with the most potent currently available
tatins (39), and the potential for any added benefit gained
y such treatment should be carefully weighed against the
ncremental cost, potential for adverse effects, and possible
rustration of those unable to achieve these goals (40).
Another issue highlighted by the authors is the less-than-
ptimal correlation between LDL cholesterol and apoB
evels in both untreated as well as statin-treated patients.
nce again the question is raised: is LDL cholesterol the
est marker for gauging CHD risk and therapeutic goals?
he use of all 3 parameters (LDL cholesterol, non–
DL-C, and apoB), as suggested by Brunzell et al. (8) for
atients with cardiometabolic risk, might be suitable for
xperts working in specialized lipid or diabetes clinics, but I
ave doubts whether this approach would be widely adoptedy most primary care practitioners. If we were to accept the
aradigm that the number of all atherogenic particles is a
ore important determinant of cardiovascular risk than the
DL cholesterol content (9), then the use of apoB as the
rimary measure of risk in all patients would make sense.
lthough some experts support this approach enthusiasti-
ally (9,23), others object to it on the grounds of assay
tandardization and availability. Ballantyne et al. (35) sug-
est using non–HDL-C as a surrogate for apoB. Although
hese 2 entities represent different aspects of the atherogenic
ipoproteins, they are highly correlated both before and
uring statin treatment. The use of a single parameter in all
atients (irrespective of triglyceride levels) for estimating
isk, deciding on the need for therapy, and gauging thera-
eutic goals has the potential to simplify the current 2-step
pproach and improve physician adherence to the guide-
ines. The assay can be performed in the nonfasting state,
nd all laboratories can (and should) report its value without
dditional cost. Finally, the name should be changed from
non–HDL-C,” which defines the atherogenic elements in
 negative way, to a more appealing title, such as “athero-
enic B lipoprotein” cholesterol.
A concluding comment is warranted about guidelines.
or the practicing clinician who attempts to stay abreast of
vidence-based patient management, it is both frustrating
nd confusing to witness the same research data being
ranslated into different treatment recommendations by
enowned committee experts (6–8,37). Although apprecia-
le effort has been made to achieve consensus among various
rganizations within each guideline committee, less consen-
us is apparent between guidelines on the same topic.
hereas diversity of opinion is a crucial component of
ell-balanced committees, the final output should provide
hysicians with a clear set of simple recommendations that
an overcome the numerous barriers to guideline implemen-
ation (41). A unified approach across the Atlantic Ocean
ould facilitate this goal.
Are we ready for these revolutionary changes?
eprint requests and correspondence: Dr. Yaakov Henkin,
epartment of Cardiology, P.O. Box 151, Soroka University
edical Center, Beer Sheva, Israel. E-mail: yaakovh@bgu.ac.il.
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